Protalix BioTherapeutics PLX Cash Flow Statement (2010-2026)

NYSE PLX
$2.57 -0.07 (-2.65%)
As of: Oct 21, 2026 · 3:59 PM EDT
Reported Financials

Protalix BioTherapeutics Quarterly Cash Flow Statement

Periods 63 quarters
Latest Jun 2026

Protalix BioTherapeutics reported cash from operations of -$10.40M and free cash flow of -$10.99M for the quarter ended Jun 2026, down 98.7% year over year. This cash flow statement covers 63 quarters of results from Jun 2010 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Jun2010 Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-4.20M-6.67M-2.29M-5.33M-3.57M-3.74M-3.13M19.34M-1.85M-6.04M-4.60M-2.20M3.24M6.49M-3.62M0.16M2.36M-5.50M18.32M3.78M
Depreciation and DepletionDep. & Depletion
0.29M0.26M0.27M0.27M0.27M0.29M0.28M0.29M0.31M0.31M0.32M0.32M0.33M0.33M0.35M0.12M0.37M0.39M0.40M0.13M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
0.64M0.10M0.08M0.07M0.08M0.08M0.08M0.07M0.06M0.06M
Depreciation & Amortization (CF)Dep. & Amort.
0.29M0.26M0.27M0.27M0.27M0.29M0.28M0.29M0.31M0.31M0.32M0.32M0.33M0.33M0.35M0.12M0.37M0.39M0.40M0.13M
Share-based CompensationStock Comp.
0.56M0.42M0.84M0.29M0.42M0.54M0.55M0.44M1.10M1.37M0.98M1.00M0.62M0.65M0.54M0.43M0.60M0.73M0.53M0.40M
Deferred Taxes
-3.13M0.04M-0.14M-0.07M0.44M-0.11M0.23M0.06M0.16M0.07M0.07M
Cash from Discontinued OperationsCash from Discont. Ops
Gains from Sales and DivestituresGains Divest
Gains from Investment SecuritiesGains Investment
Other non-cash itemsOther Non-Cash
0.22M0.50M0.57M0.14M0.12M-0.05M0.02M0.08M0.72M0.75M0.48M0.67M0.26M0.21M-0.17M0.16M0.19M0.72M0.33M0.13M
Change in Working Capital
Change in ReceivablesChange Receivables
2.49M-3.04M2.31M-2.39M5.77M-4.50M-3.82M3.70M4.31M-3.76M-1.75M7.05M-8.38M0.75M2.28M4.64M4.85M-5.88M-6.41M15.03M
Change in InventoryChange Inventory
1.09M3.22M-1.36M-0.09M-1.95M2.24M3.50M-0.67M1.95M-2.54M3.30M-1.63M-3.52M4.04M-1.74M1.63M0.12M4.47M4.75M1.82M
Change in Accured ExpensesChange Accured Exp.
1.61M1.32M-1.01M-3.85M0.43M-0.37M0.35M3.29M0.18M1.48M-1.41M1.61M-0.87M1.37M-1.28M-0.61M-2.14M4.33M0.82M3.35M
Change in Other Operating AssetsOther Assets Change
0.07M0.00M0.00M0.00M-0.03M0.03M0.01M-0.01M0.01M0.00M0.01M0.01M-0.01M-0.02M-0.02M-0.02M-0.02M0.75M0.06M2.15M
Change in Other Operating LiabilitiesOther Liabilities Change
1.64M-0.72M-2.64M-2.90M-1.62M-1.39M-11.79M11.04M1.66M
Other Working Capital ChangesOther WC Changes
1.57M-0.71M-2.64M0.00M-2.88M-1.64M-1.40M-11.78M-0.01M0.00M11.03M1.65M0.01M0.02M0.02M0.02M0.02M-0.75M-0.06M-2.15M
Other Operating ActivitiesOther Ops.
0.14M-0.07M0.04M0.06M0.04M-0.04M0.08M0.23M0.05M0.03M0.02M1.43M0.01M0.17M0.05M0.04M0.39M0.69M0.19M
Cash from OperationsCash from Ops.
-1.88M-5.09M-5.83M-7.36M-9.20M-2.61M-3.00M4.97M-6.89M3.60M4.19M-3.61M4.11M3.99M-5.06M-5.23M-3.73M2.03M22.03M-10.40M
Investing Activities
Capital ExpendituresCapex
0.34M0.45M0.23M0.13M0.06M0.21M0.25M0.20M0.45M0.25M0.60M0.17M0.09M0.43M0.31M0.43M0.50M0.40M0.76M0.59M
Sales of Property, Plant and EquipmentPP&E (Sale)
Change in Property, Plant and EquipmentChange in PP&E
-0.34M-0.45M-0.23M-0.13M-0.06M-0.21M-0.25M-0.20M-0.45M-0.25M-0.60M-0.17M-0.09M-0.43M-0.31M-0.43M-0.50M-0.40M-0.76M-0.59M
Purchase of InvestmentsInvestments Purchased
5.00M3.00M
Change in Acquisitions & DivestmentsChange Acquisitions
20.00M16.00M5.00M15.42M10.00M
Other Investing ActivitiesOther investing
-0.03M-0.03M-0.03M0.49M-0.03M0.17M-0.02M-0.02M-0.01M-0.09M-0.01M-0.01M-0.01M0.11M-0.01M-0.01M-0.01M-0.01M-0.01M-0.03M
Cash from Investing ActivitiesCash from Investing
4.63M37.44M-16.26M0.36M5.91M4.95M4.73M-0.22M-20.88M-0.34M-0.61M-0.18M20.33M-15.32M-0.31M-0.44M-0.50M-1.11M4.22M-3.64M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
Long-Term Debt RepaymentsLT Debt Repayment
25.99M4.05M
Non-Current Debt
-25.99M-4.05M
Net Debt Issuances and RepaymentsNet Debt Issuance
-25.99M-4.05M
Change in Capital Stock
Common Stock IssuedStock Issued
1.52M4.08M14.23M10.43M5.08M4.10M0.15M0.15M
Net Shares Issued and RepurchasedNet Shares Issued
1.52M4.08M14.23M10.43M5.08M4.10M0.15M0.15M
Net Equity Issued and RepurchasedNet Equity Issued
1.52M4.08M14.23M10.43M5.08M4.10M0.15M0.15M
Cash from Financing ActivitiesCash from Financing
-25.99M-4.05M1.52M4.08M14.23M10.43M3.63M5.08M4.10M0.15M0.15M
Additional items
Exchange Rate EffectFX Effect
0.00M0.04M-0.01M-0.04M-0.03M-0.04M-0.04M-0.01M-0.03M-0.01M-0.02M0.00M0.05M-0.01M0.00M-0.01M-0.03M-0.08M0.45M
Change in Cash
-23.24M28.34M-22.10M-4.40M-1.77M6.39M15.93M15.15M-27.78M3.23M3.58M-3.81M4.01M-7.65M-0.30M-1.56M-4.25M1.03M26.32M-13.58M
Ending Cash Balance
10.64M38.99M16.89M12.49M10.72M17.11M33.04M48.18M20.41M23.63M27.21M23.40M27.41M19.76M19.46M17.90M13.65M14.68M41.00M27.42M
Free Cash FlowFCF
-2.22M-5.54M-6.06M-7.48M-9.26M-2.82M-3.25M4.77M-7.34M3.35M3.59M-3.78M4.02M3.57M-5.36M-5.66M-4.23M1.63M21.26M-10.99M
Net Cash FlowNCF
-23.24M28.30M-22.09M-7.00M-1.77M6.42M15.97M15.18M-27.77M3.25M3.58M-3.79M24.43M-7.70M-0.29M-1.57M-4.24M1.06M26.40M-14.04M
Interest Paid
1.12M0.12M1.12M1.08M1.08M0.90M0.77M0.00M0.77M0.77M
Income Taxes PaidTaxes Paid
0.00M2.50M

Protalix BioTherapeutics Cash Flow Statement API

Pull Protalix BioTherapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=PLX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY